Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Sold by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. trimmed its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 5.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 61,079 shares of the specialty pharmaceutical company's stock after selling 3,604 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. owned approximately 0.10% of Jazz Pharmaceuticals worth $7,522,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of JAZZ. Fuller & Thaler Asset Management Inc. increased its holdings in Jazz Pharmaceuticals by 117.4% in the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 939,351 shares of the specialty pharmaceutical company's stock valued at $115,681,000 after buying an additional 507,234 shares during the last quarter. Darwin Global Management Ltd. acquired a new position in shares of Jazz Pharmaceuticals during the 4th quarter worth about $59,668,000. Dimensional Fund Advisors LP increased its holdings in shares of Jazz Pharmaceuticals by 18.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,035,070 shares of the specialty pharmaceutical company's stock valued at $250,619,000 after acquiring an additional 320,724 shares during the last quarter. Ameriprise Financial Inc. raised its position in shares of Jazz Pharmaceuticals by 20.9% during the 4th quarter. Ameriprise Financial Inc. now owns 1,827,658 shares of the specialty pharmaceutical company's stock worth $225,076,000 after acquiring an additional 315,608 shares in the last quarter. Finally, GMT Capital Corp raised its position in shares of Jazz Pharmaceuticals by 140.0% during the 4th quarter. GMT Capital Corp now owns 508,800 shares of the specialty pharmaceutical company's stock worth $62,659,000 after acquiring an additional 296,800 shares in the last quarter. 89.14% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the company. Morgan Stanley lowered their price target on Jazz Pharmaceuticals from $183.00 to $166.00 and set an "overweight" rating for the company in a report on Wednesday, May 7th. Wells Fargo & Company upgraded shares of Jazz Pharmaceuticals from an "equal weight" rating to an "overweight" rating and upped their target price for the company from $130.00 to $170.00 in a report on Thursday, February 13th. Wall Street Zen downgraded shares of Jazz Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday, May 15th. UBS Group upgraded shares of Jazz Pharmaceuticals from a "neutral" rating to a "buy" rating and lifted their price target for the stock from $145.00 to $179.00 in a research note on Friday, March 7th. Finally, HC Wainwright boosted their price target on shares of Jazz Pharmaceuticals from $200.00 to $217.00 and gave the company a "buy" rating in a research report on Monday, March 10th. Two analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $182.79.

Jazz Pharmaceuticals Stock Performance

Jazz Pharmaceuticals stock traded up $0.40 during midday trading on Friday, hitting $108.22. 204,223 shares of the company's stock were exchanged, compared to its average volume of 1,083,158. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. The stock has a market cap of $6.67 billion, a price-to-earnings ratio of 15.23, a price-to-earnings-growth ratio of 1.04 and a beta of 0.38. Jazz Pharmaceuticals plc has a 12-month low of $95.49 and a 12-month high of $148.06. The firm's 50 day simple moving average is $113.50 and its 200 day simple moving average is $121.91.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last announced its earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share for the quarter, missing the consensus estimate of $4.65 by ($2.97). The business had revenue of $897.84 million for the quarter, compared to analyst estimates of $984.16 million. Jazz Pharmaceuticals had a return on equity of 29.30% and a net margin of 11.60%. Jazz Pharmaceuticals's quarterly revenue was down .5% on a year-over-year basis. During the same quarter last year, the company posted $2.68 EPS. Equities research analysts predict that Jazz Pharmaceuticals plc will post 16.96 EPS for the current year.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 3,800 shares of the business's stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $144.87, for a total value of $550,506.00. Following the transaction, the executive vice president now directly owns 33,318 shares of the company's stock, valued at approximately $4,826,778.66. The trade was a 10.24% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Seamus Mulligan acquired 100,000 shares of the business's stock in a transaction on Friday, May 9th. The shares were purchased at an average price of $98.26 per share, with a total value of $9,826,000.00. Following the transaction, the director now owns 100,000 shares in the company, valued at $9,826,000. The trade was a ∞ increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders sold 28,236 shares of company stock valued at $3,956,190. 4.20% of the stock is owned by company insiders.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.